{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:10:09Z","timestamp":1791382209818,"version":"4.3.3"},"reference-count":49,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2009,6,1]],"date-time":"2009-06-01T00:00:00Z","timestamp":1243814400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2009,6]]},"DOI":"10.1016\/j.ejca.2009.03.013","type":"journal-article","created":{"date-parts":[[2009,4,8]],"date-time":"2009-04-08T08:46:21Z","timestamp":1239180381000},"page":"1709-1720","source":"Crossref","is-referenced-by-count":59,"title":["Growth inhibitory and anti-tumour activities of OSU-03012, a novel PDK-1 inhibitor, on vestibular schwannoma and malignant schwannoma cells"],"prefix":"10.1016","volume":"45","author":[{"given":"Tina X.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark D.","family":"Packer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena M.","family":"Akhmametyeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel K.","family":"Kulp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Shih","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Giovannini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abraham","family":"Jacob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D. Bradley","family":"Welling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Long-Sheng","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2009.03.013_bib1","series-title":"Surgery of the cerebellopontine angle","article-title":"The biology and genetics of vestibular schwannomas","author":"Welling","year":"2008"},{"key":"10.1016\/j.ejca.2009.03.013_bib2","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1038\/363515a0","article-title":"Alteration in a new gene encoding a putative membrane-organising protein causes neurofibromatosis type 2","volume":"363","author":"Rouleau","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2009.03.013_bib3","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/0092-8674(93)90406-G","article-title":"A novel Moesin-, Exrin-, Radixin-like gene is a candidate for the neurofibromatosis 2 tumor-suppressor","volume":"72","author":"Trofatter","year":"1993","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2009.03.013_bib4","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1097\/00129492-200209000-00022","article-title":"CDNA microarray analysis of vestibular schwannomas","volume":"23","author":"Welling","year":"2002","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.ejca.2009.03.013_bib5","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0140-6736(02)09521-1","article-title":"Malignant transformation of a vestibular schwannoma after gamma knife radiosurgery","volume":"360","author":"Shin","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.ejca.2009.03.013_bib6","series-title":"Diagnostic soft tissue pathology","author":"Miettinen","year":"2003"},{"key":"10.1016\/j.ejca.2009.03.013_bib7","first-page":"125","article-title":"Malignant nerve sheath tumour of the jugular foramen followed by meningeal dissemination in a patient with neurofibromatosis","volume":"10","author":"Takenobu","year":"1993","journal-title":"Brain Tumor Pathol"},{"issue":"3","key":"10.1016\/j.ejca.2009.03.013_bib8","first-page":"298","article-title":"Radiation-induced malignant triton tumor associated with severe spinal cord compression. Case report and review of the literature","volume":"100","author":"Mut","year":"2004","journal-title":"J Neurosurg"},{"key":"10.1016\/j.ejca.2009.03.013_bib9","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1215\/15228517-2007-027","article-title":"Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature","volume":"9","author":"Balasubramaniam","year":"2007","journal-title":"Neuro-Oncol"},{"key":"10.1016\/j.ejca.2009.03.013_bib10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1007\/s00701-008-1563-4","article-title":"Malignant trigeminal schwannoma extending into the anterior skull base","volume":"150","author":"Chibbaro","year":"2008","journal-title":"Acta Neurochir (Wien)"},{"key":"10.1016\/j.ejca.2009.03.013_bib11","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1002\/1097-0142(19810515)47:10<2503::AID-CNCR2820471033>3.0.CO;2-3","article-title":"Malignant schwannoma \u2013 clinical characteristics, survival, and response to therapy","volume":"47","author":"Sordillo","year":"1981","journal-title":"Cancer"},{"key":"10.1016\/j.ejca.2009.03.013_bib12","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1002\/(SICI)1097-0347(199910)21:7<663::AID-HED12>3.0.CO;2-4","article-title":"Malignant triton tumor of the head and neck: a case report and review of the literature","volume":"21","author":"Victoria","year":"1999","journal-title":"Head Neck"},{"key":"10.1016\/j.ejca.2009.03.013_bib13","doi-asserted-by":"crossref","first-page":"2265","DOI":"10.1101\/gad.1335605","article-title":"Membrane organization and tumorigenesis \u2013 the NF2 tumor suppressor, Merlin","volume":"19","author":"McClatchey","year":"2005","journal-title":"Genes Dev"},{"key":"10.1016\/j.ejca.2009.03.013_bib14","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1097\/00005537-200209000-00004","article-title":"Retinoblastoma-cyclin-dependent kinase pathway deregulation in vestibular schwannomas","volume":"112","author":"Lasak","year":"2002","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ejca.2009.03.013_bib15","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1111\/j.1365-2990.2006.00769.x","article-title":"Differential gene expression between human schwannoma and control Schwann cells","volume":"32","author":"Hanemann","year":"2006","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.ejca.2009.03.013_bib16","unstructured":"Manent J, Kaiser S, Lallemand D, et al. NF2 molecular dissection across species and models: evidence for activation of the PI3K\/Akt pathway, a mechanism previously correlated with Schwann cell differentiation, survival and tumorigenesis. In: The Children\u2019s Tumor Foundation international neurofibromatosis consortium; 2006 [abstract P27]."},{"key":"10.1016\/j.ejca.2009.03.013_bib17","unstructured":"Lee T, Jacob A, Packer M, Chen CS, Welling DB, Chang LS. OSU03012 and (S)-HDAC-42, two novel inhibitors of the PI3K\/AKT pathway, are potential therapeutic agents for vestibular schwannomas. In: The Children\u2019s Tumor Foundation-sponsored NF conference; 2007 [abstract P36]."},{"key":"10.1016\/j.ejca.2009.03.013_bib18","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1038\/ncb1641","article-title":"Akt phosphorylation regulates the tumour-suppressor merlin through ubiquitination and degradation","volume":"9","author":"Tang","year":"2007","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.ejca.2009.03.013_bib19","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/mao.0b013e31816021f7","article-title":"Phosphatidylinositol 3-kinase\/AKT pathway activation in human vestibular schwannoma","volume":"29","author":"Jacob","year":"2008","journal-title":"Otol Neurotol"},{"key":"10.1016\/j.ejca.2009.03.013_bib20","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.drup.2007.11.003","article-title":"Targeting the PI3K\/Akt\/mTOR pathway: effective combinations and clinical considerations","volume":"11","author":"LoPiccolo","year":"2008","journal-title":"Drug Resist Updat"},{"key":"10.1016\/j.ejca.2009.03.013_bib21","doi-asserted-by":"crossref","first-page":"4309","DOI":"10.1158\/0008-5472.CAN-03-4063","article-title":"From the cyclooxygenase-2 inhibitor celecoxib to a novel class of 3-phosphoinositide-dependent protein kinase-1 inhibitors","volume":"64","author":"Zhu","year":"2004","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2009.03.013_bib22","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1182\/blood-2004-05-1957","article-title":"A novel celecoxib derivative, OSU03012, induces cytotoxicity in primary CLL cells and transformed B-cell lymphoma cell line via a caspase- and Bcl-2-independent mechanism","volume":"105","author":"Johnson","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ejca.2009.03.013_bib23","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.lungcan.2005.12.003","article-title":"Cytotoxicity of a non-cyclooxygenase-2 inhibitory derivative of celecoxib in non-small-cell lung cancer A549 cells","volume":"52","author":"Tong","year":"2006","journal-title":"Lung cancer"},{"key":"10.1016\/j.ejca.2009.03.013_bib24","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1124\/mol.107.037556","article-title":"OSU-03012, A celecoxib derivative, directly targets p21 activated kinase","volume":"72","author":"Porchia","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ejca.2009.03.013_bib25","doi-asserted-by":"crossref","first-page":"4750","DOI":"10.1158\/1078-0432.CCR-07-0136","article-title":"OSU-03012, a novel celecoxib derivative, is cytotoxic to myeloma cells and acts through multiple mechanisms","volume":"13","author":"Zhang","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ejca.2009.03.013_bib26","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1523\/JNEUROSCI.11-08-02433.1991","article-title":"Isolation and functional characterization of Schwann cells derived from adult peripheral nerve","volume":"11","author":"Morrissey","year":"1991","journal-title":"J Neurosci"},{"key":"10.1016\/j.ejca.2009.03.013_bib27","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1101\/gad.14.13.1617","article-title":"Conditional biallelic Nf2 mutation in the mouse promotes manifestations of human neurofibromatosis type 2","volume":"14","author":"Giovannini","year":"2000","journal-title":"Genes Dev"},{"key":"10.1016\/j.ejca.2009.03.013_bib28","doi-asserted-by":"crossref","first-page":"2576","DOI":"10.1128\/MCB.17.5.2576","article-title":"Induction of cell proliferation in quiescent NIH 3T3 cells by oncogenic c-Raf-1","volume":"17","author":"Kerkhoff","year":"1997","journal-title":"Mol Cell Biol"},{"key":"10.1016\/j.ejca.2009.03.013_bib29","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1006\/geno.2001.6672","article-title":"Multiple transcription initiation sites, alternative splicing, and differential polyadenylation contribute to the complexity of human neurofibromatosis 2 transcripts","volume":"79","author":"Chang","year":"2002","journal-title":"Genomics"},{"key":"10.1016\/j.ejca.2009.03.013_bib30","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1097\/01.mlg.0000240185.14224.7d","article-title":"Growth of benign and malignant schwannoma xenografts in severe combined immunodeficiency mice","volume":"116","author":"Chang","year":"2006","journal-title":"Laryngoscope"},{"key":"10.1016\/j.ejca.2009.03.013_bib31","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1002\/glia.20330","article-title":"Cyclic AMP synergistically enhances neuregulin-dependent ERK and Akt activation and cell cycle progression in Schwann cells","volume":"53","author":"Monje","year":"2006","journal-title":"Glia"},{"issue":"Suppl. 4","key":"10.1016\/j.ejca.2009.03.013_bib32","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/S1359-6349(06)70607-3","article-title":"Poster 602 \u2013 pharmacokinetics of Akt inhibitor NSC728209 in the rat by LC\/MS\/MS method","author":"Chan","year":"2006","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ejca.2009.03.013_bib33","doi-asserted-by":"crossref","first-page":"E187","DOI":"10.1152\/ajpendo.00011.2005","article-title":"PDK2: the missing piece in the receptor tyrosine kinase signaling pathway puzzle","volume":"289","author":"Dong","year":"2005","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"10.1016\/j.ejca.2009.03.013_bib34","doi-asserted-by":"crossref","first-page":"17702","DOI":"10.1074\/jbc.M802589200","article-title":"PDK1 regulates cell proliferation and cell cycle progression through control of cyclin D1 and p27kip1 expression","volume":"283","author":"Nakamura","year":"2008","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2009.03.013_bib35","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1002\/ijc.20639","article-title":"Celecoxib derivatives induce apoptosis via the disruption of mitochondrial membrane potential and activation of caspase 9","volume":"113","author":"Ding","year":"2005","journal-title":"Int J Cancer"},{"key":"10.1016\/j.ejca.2009.03.013_bib36","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1124\/mol.106.025007","article-title":"OSU-03012 promotes caspase-independent but PERK-, cathepsin B-, BID-, and AIF-dependent killing of transformed cells","volume":"70","author":"Yacoub","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.ejca.2009.03.013_bib37","doi-asserted-by":"crossref","first-page":"18200","DOI":"10.1073\/pnas.0405971102","article-title":"Neurofibromatosis 2 (NF2) tumor suppressor merlin inhibits phosphatidylinositol 3-kinase through binding to PIKE-L","volume":"101","author":"Rong","year":"2005","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.ejca.2009.03.013_bib38","doi-asserted-by":"crossref","first-page":"7729","DOI":"10.1038\/sj.onc.1209046","article-title":"SV40 large T antigen targets multiple cellular pathways to elicit cellular transformation","volume":"24","author":"Ahuja","year":"2005","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2009.03.013_bib39","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S1534-5807(01)00009-0","article-title":"The Nf2 tumor suppressor, merlin, functions in Rac-dependent signaling","volume":"1","author":"Shaw","year":"2001","journal-title":"Dev Cell"},{"key":"10.1016\/j.ejca.2009.03.013_bib40","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/0008-5472.CAN-06-1608","article-title":"Merlin\/neurofibromatosis type 2 suppresses growth by inhibiting the activation of Ras and Rac","volume":"67","author":"Morrison","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2009.03.013_bib41","doi-asserted-by":"crossref","first-page":"10394","DOI":"10.1074\/jbc.M200083200","article-title":"Merlin phosphorylation by p21-activated kinase 2 and effects of phosphorylation on merlin localization","volume":"277","author":"Kissil","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2009.03.013_bib42","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1074\/jbc.C100553200","article-title":"P21-activated kinase links Rac\/Cdc42 signaling to merlin","volume":"277","author":"Xiao","year":"2002","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ejca.2009.03.013_bib43","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/sj.onc.1207142","article-title":"Effect of merlin phosphorylation on neurofibromatosis 2 (NF2) gene function","volume":"23","author":"Surace","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejca.2009.03.013_bib44","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1097\/00130404-200401000-00006","article-title":"A clue to the therapy of neurofibromatosis type 2: NF2\/merlin is a PAK1 inhibitor","volume":"10","author":"Hirokawa","year":"2004","journal-title":"Cancer J"},{"key":"10.1016\/j.ejca.2009.03.013_bib45","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1126\/science.282.5392.1318","article-title":"Regulation of cell death protease caspase-9 by phosphorylation","volume":"282","author":"Cardone","year":"1998","journal-title":"Science"},{"key":"10.1016\/j.ejca.2009.03.013_bib46","doi-asserted-by":"crossref","first-page":"9348","DOI":"10.1158\/0008-5472.CAN-08-1642","article-title":"OSU-03012, a novel celecoxib derivative, induces reactive oxygen species-related autophagy in hepatocellular carcinoma","volume":"68","author":"Gao","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2009.03.013_bib47","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1158\/1535-7163.MCT-07-0434","article-title":"Sensitizing estrogen receptor-negative breast cancer cells to tamoxifen with OSU-03012, a novel celecoxib-derived phosphoinositide-dependent protein kinase-1\/Akt signaling inhibitor","volume":"7","author":"Weng","year":"2008","journal-title":"Mol Cancer Ther"},{"key":"10.1016\/j.ejca.2009.03.013_bib48","doi-asserted-by":"crossref","first-page":"2820","DOI":"10.1158\/0008-5472.CAN-07-1336","article-title":"Targeting endoplasmic reticulum stress and Akt with OSU-03012 and gefitinib or erlotinib to overcome resistance to epidermal growth factor receptor inhibitors","volume":"68","author":"Wang","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2009.03.013_bib49","doi-asserted-by":"crossref","first-page":"4021","DOI":"10.1182\/blood-2004-07-2967","article-title":"Synergistic interactions between imatinib mesylate and the novel phosphoinositide-dependent kinase-1 inhibitor OSU-03012 in overcoming imatinib mesylate resistance","volume":"105","author":"Tseng","year":"2005","journal-title":"Blood"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909001956?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804909001956?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,5,24]],"date-time":"2023-05-24T19:51:14Z","timestamp":1684957874000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804909001956"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,6]]},"references-count":49,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2009,6]]}},"alternative-id":["S0959804909001956"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2009.03.013","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2009,6]]}}}